Σφακιανάκης Αλέξανδρος
ΩτοΡινοΛαρυγγολόγος
Αναπαύσεως 5 Άγιος Νικόλαος
Κρήτη 72100
00302841026182
00306932607174
alsfakia@gmail.com

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τετάρτη 21 Οκτωβρίου 2020

 


Interval Breast Cancers Tied to Worse Outcomes
Risk for breast cancer death more than threefold higher for interval versus screen - detected cancer (Source: The Doctors Lounge - Oncology)
The Doctors Lounge - Oncology
6h
Insurance Tied to Odds of Cancer Surgery at High - Volume Centers
Uninsured, Medicare - , Medicaid - insured less likely to receive surgical cancer care at high - volume hospital (Source: The Doctors Lounge - Oncology)
The Doctors Lounge - Oncology
6h
Linked Color Imaging Detects More Neoplastic Upper GI Lesions
More neoplastic lesions initially diagnosed in the examination group undergoing LCI first (Source: The Doctors Lounge - Oncology)
The Doctors Lounge - Oncology
21h
CDC: One - Year Survival 96.1 Percent for Male Breast Cancer
Relative survival varies by stage at diagnosis, from 98.7 to 25.9 percent for localized and distant stage, respectively (Source: The Doctors Lounge - Oncology)
The Doctors Lounge - Oncology
21h
Actor Jeff Bridges Shares Lymphoma Diagnosis
(Source: The Doctors Lounge - Oncology)
The Doctors Lounge - Oncology
21h
Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
AbstractCoronavirus disease 2019 (COVID-19) was declared to be a global pandemic by the World Health Organization on March 11, 2020. On April 7, 2020, a state of emergency was declared in Japan, as had been by other nations worldwide. This unprecedented crisis has profound implications for patients undergoing chemotherapy and for practicing healthcare professionals. Various reports have shown data indicating that cancer patients with COVID-19 have high morbidity and mortality rates. In order to reduce...
International Journal of Clinical Oncology
6h
Safety and efficacy of S-1 plus oxaliplatin 130  mg/m 2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A)
ConclusionsThis study represents the first evaluation of SOX130 in patients with HER2-negative AGC. SOX130 showed an acceptable safety profile, but the prespecified statistical efficacy targets were not achieved. (Source: International Journal of Clinical Oncology)
International Journal of Clinical Oncology
6h
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
ConclusionsThis study met its primary endpoint of PFS, which is comparable to the results of the C-TASK FORCE study. The TAS-102 and bevacizumab combination has the potential to be a therapeutic option for third-line treatment of metastatic CRC. (Source: International Journal of Clinical Oncology)
International Journal of Clinical Oncology
20h
Assessing Dental Students ’ HPV Health Literacy and Intention to Engage in HPV-Related Oropharyngeal Cancer Prevention
This study aims to identify current HPV-related curricula taught across US dental schools and evaluate HPV health literacy and intention to engage in HPV prevention among US dental students. The dental school curricula included responses from 40 Academic Deans (61% response rate). The 4-item survey focused on understanding HPV-related content in dental school curricula and was administered via Qualtrics. A 31-item paper survey was administered to dental students (N = 109) at a southeastern dental...
Journal of Cancer Education
6h
Rapid Adaptation of Cancer Education in Response to the COVID-19 Pandemic: Evaluation of a Live Virtual Statistics and Research Skills Workshop for Oncology Trainees
This study aimed to evaluate trainee opinions around the educational value of the workshop, logistical aspects and impact on interactivity. A post-course on-line survey was completed by 26/42 trainee attendees (response rate 62%). For five pre-specified learning outcomes (LO), 58 to 69% of trainees agreed that the LO was completely or largely met (Likert scores 6 and 7 on a scale 1  = not met at all; 7 = completely met). All trainees felt that logistical aspects of the workshop including organisation,...
Journal of Cancer Education
6h
Factors Associated with Cancer Screening Among Hopi Men
This study evaluated cancer screening behaviors in 102 Hopi men who were 50  years of age or older from the Hopi Survey of Cancer and Chronic Disease. Reported cancer screening frequencies were 15.7%, 45.1%, and 35.3% for fecal occult blood test (FOBT), colonoscopy, and prostate-specific antigen (PSA) test, respectively. Among men who reported having had a FOBT, 81.2% had the test more than 1 year ago. Among men who reported a colonoscopy, 60.8% had colonoscopy within the past 3 years. Similarly,...
Journal of Cancer Education
21h
Early Melanoma Detection in Primary Care: Clinical Recognition of Melanoma is Not Enough, One Must Also Learn the Basics
This study aimed to determine whether the adjunct of teaching basic knowledge of pigmented skin lesions (PSL) to the training in melanoma diagnosis improves the GPs ’ diagnostic accuracy of melanoma. An interventional prospective study was conducted over a 3-month period where GPs attended a 2-h training course. The 1st session taught clinical melanoma recognition and the 2nd session instructed basic knowledge of PSL. Prior to training, after the 1st, and after the 2nd session, GPs were asked to...
Journal of Cancer Education
21h
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable Non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer death worldwide. At the time of initial diagnosis approximately 30% of patients have locally advanced disease (stage III) which is often unresectable. (1,2,3) Chemoradiotherapy (CRT) including platinum-based doublet chemotherapy used to be the standard of care for patients with a good performance status and unresectable stage III NSCLC. (4,5) Although CRT is performed with curative intent, patient prognosis has been poor...
Lung Cancer
6h
Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells
Clinical studies have indicated that EGFR mutations and ALK rearrangements are associated with low response rates to blockade of the PD-1 pathway [1,2]. A correlation between EGFR mutations and low rates of concurrent PD-L1 expression and CD8+ tumor-infiltrating lymphocytes (TILs) may cause inferior responses to PD-1 blockade [3,4]. The underlying mechanism by which ALK rearrangements lead to a low rate of responsiveness to PD-1 therapies remains unclear. Initial interest in inhibiting the PD-1 axis...
Lung Cancer
21h
Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma
Immune-related genes is closely related to the occurrence and prognosis of head and neck squamous cell carcinoma (HNSCC). At the same time, immune-related genes have great potential as prognostic markers in ma... (Source: BMC Cancer)
BMC Cancer
6h
An immunochemistry-based screen for chemical inhibitors of DNA-protein interactions and its application to human CGGBP1
Inhibition of DNA-binding of proteins by small-molecule chemicals holds immense potential in manipulating the activities of DNA-binding proteins. Such a chemical inhibition of DNA-binding of proteins can be us... (Source: BMC Cancer)
BMC Cancer
6h
Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer
Peritoneal metastasis (PM) in gastric cancer (GC) is characterized by diffusely infiltrating and proliferating cancer cells accompanied by extensive stromal fibrosis in the peritoneal space. The prognosis of G... (Source: BMC Cancer)
BMC Cancer
6h
Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom
ConclusionsCompared with women with no history of cancer, breast cancer survivors report more problems with cognition, sexual function, fatigue, and anxiety, particularly where their cancer was advanced and/or treated with chemotherapy.Implications for Cancer SurvivorsBreast cancer survivors with more advanced disease and/or treated with chemotherapy should be closely monitored and, when possible, offered evidence-based intervention for fatigue, cognitive dysfunction, and sexual problems. (Source:...
Journal of Cancer Survivorship
6h
pCR in HER2+ Breast Cancer Predicts Long-Term Survival pCR in HER2+ Breast Cancer Predicts Long-Term Survival
A pathologic complete response to targeted therapy in HER2-positive breast cancer portends good long-term outcomes and may be a marker of cure, according to the final results of a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Medscape Hematology-Oncology Headlines
6h
Prostate cancer tumour control probability modelling for external beam radiotherapy based on multi-parametric MRI-GTV definition
To evaluate the applicability and estimate the radiobiological parameters of linear-quadratic Poisson tumour control probability (TCP) model for primary prostate cancer patients for two relevant target structu... (Source: Radiation Oncology)
Radiation Oncology
7h
A non-invasive ultrasound imaging method to measure acute radiation-induced bladder wall thickening in rats
Methods for the non-invasive quantification of changes in bladder wall thickness as potential predictors of radiation cystitis in pre-clinical research would be desirable. The use of ultrasound for this aim se... (Source: Radiation Oncology)
Radiation Oncology
7h
Evaluation of OAR dose sparing and plan robustness of beam-specific PTV in lung cancer IMRT treatment
Margins are employed in radiotherapy treatment planning to mitigate the dosimetric effects of geometric uncertainties for the clinical target volume (CTV). Here, we proposed a margin concept that takes into co... (Source: Radiation Oncology)
Radiation Oncology
7h
Downregulation of microRNA-324-3p inhibits lung cancer by blocking the NCAM1-MAPK axis through ALX4
Cancer Gene Therapy, Published online: 21 October 2020; doi:10.1038/s41417-020-00231-2Downregulation of microRNA-324-3p inhibits lung cancer by blocking the NCAM1-MAPK axis through ALX4
Cancer Gene Therapy - Issue - nature.com science feeds
7h
Downregulation of microRNA-324-3p inhibits lung cancer by blocking the NCAM1-MAPK axis through ALX4
Cancer Gene Therapy - Issue - nature.com science feeds
10h
Bioequivalence study of 20-mg and 100-mg temozolomide capsules (TOZ309 and Temodal ® ) in glioma patients in China
Abstract Background Temozolomide is an alkylating agent approved by the U.S. Food and Drug Administration in 1999 for the treatment of patients with primary brain tumors. The aim of this study was to confirm the bioequivalence and safety of two strengths (20–100 mg) of generic temozolomide in the form of TOZ039 and Temodal® capsules administered to brain tumor patients. ...
Latest Results for Cancer Chemotherapy and Pharmacology
8h
The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo
Abstract Purpose Recent studies have shown that TIM3 plays an important role in T-cell failure, which is closely related to the resistance to anti-programmed cell death protein 1 (PD-1) treatment. However, there have been no reports on the application of peptide blockers to TIM3. In this study, we endeavored to identify the in vitro and in vivo anti-tumor activities of a TIM3-targeting peptide screened from the phage peptide library....
Latest Results for Cancer Chemotherapy and Pharmacology
16h
Tumor microenvironment, immune response and post-radiotherapy tumor clearance
Abstract Radiotherapy is the treatment of choice for many cancer patients. Residual tumor leads to local recurrence after a period of an equilibrium created between proliferating, quiescent and dying cancer cells. The tumor microenvironment is a main obstacle for the efficacy of radiotherapy, as impaired blood flow leads to hypoxia, acidity and reduced accessibility of radiosensitizers. Eradication of remnant disease is an intractable clinical quest. After more than a century...
Clinical and translational oncology
9h
100% peer review in radiation oncology: is it feasible?
Abstract Purpose Peer review has been proposed as a strategy to ensure patient safety and plan quality in radiation oncology. Despite its potential benefits, barriers commonly exist to its optimal implementation in daily clinical routine. Our purpose is to analyze peer-review process at our institution. Methods and materials Based on...
Clinical and translational oncology
9h
FHOD3 promotes carcinogenesis by regulating RhoA/ROCK1/LIMK1 signaling pathway in medulloblastoma
Abstract Purpose Medulloblastoma (MB) is a malignant brain disease in young children. The overall survival of MB patients is disappointing due to absence of effective therapeutics and this could be attributed to the lack of molecular mechanism underlying MB. FHOD3 was an important gene during cardio-genesis and was reported to promote cell migration in cancer. However, its role in MB is not clear to date. ...
Clinical and translational oncology
9h
Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer
Abstract Purpose Patients presenting with lymphovascular space invasion (LVSI) had an absolute decrease in survival. In our present study, the potential roles of LVSI on tumor characteristics was explored to predict the difference in the prognosis of ER and HER2 positive T1 tumors. Methods A total of 142 breast cancer patients diagnosed...
Clinical and translational oncology
9h
LncRNA DCST1-AS1 downregulates miR-29b through methylation in glioblastoma (GBM) to promote cancer cell proliferation
Abstract Introduction The role of DCST1-AS1 has been investigated in several types of cancer, while the role of DCST1-AS1 in glioblastoma (GBM) is unclear. This study aimed to investigate the role of DCST1-AS1 in GBM. Methods GBM and paired non-tumor tissues were collected from 62 GBM patients. Expression levels of DCST1-AS1 and miR-29b...
Clinical and translational oncology
9h
Latest progress in molecular biology and treatment in genitourinary tumours
Abstract The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been...
Clinical and translational oncology
9h
hsa_circ_0121582 inhibits leukemia growth by dampening Wnt/β-catenin signaling
Abstract Purpose The prognosis of AML patients with chemotherapy is poor, especially those who are insensitive to and resistant to chemotherapy drugs. To clarify the underlying pathogenesis of AML and provide new therapeutic targets for clinical treatment, we explore the role of circRNA in leukemia. Methods High-throughput circRNA sequencing...
Clinical and translational oncology
9h
Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer
Abstract Background Brigatinib is a potent ROS1 inhibitor. The existing data on its clinical activity in ROS1-rearranged non-small cell lung cancer (NSCLC) are limited to four cases. Methods Six patients with ROS1-rearranged advanced NSCLC treated with brigatinib were identified through search of the internal databases of four participating...
Clinical and translational oncology
9h
Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy
Abstract Purpose Locally advanced non-small cell lung cancer (LA-NSCLC) is frequently treated with chemoradiotherapy (CRT). Despite the efforts, long-term outcomes are poor, and novel therapies have been introduced to improve results. Biomarkers are needed to detect early treatment failure and plan future follow-up and therapies. Our aim is to evaluate the role of dynamics of neutrophil-to-lymphocyte ratio (NLR) in patients with...
Clinical and translational oncology
9h
FAM83H overexpression predicts worse prognosis and correlates with less CD8 + T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer
Abstract Background Family with sequence similarity 83 members H (FAM83H) is one member of Family with sequence similarity 83 (FAM83) family, which possess oncogenic properties in several types of cancer. However, the potential function of FAM83H in pancreatic cancer (PC) still remain unknown. Aim This study aims to explore the role of...
Clinical and translational oncology
9h
Indicators of a pro-tumor immune response are evident at early stages of breast cancer
Abstract With advances in checkpoint inhibitor and CAR T-cell therapies, among other advances in immunotherapy, this is an exciting time to be a tumor immunologist. We are witnessing the transition of decades of work at the bench leading to substantial success in the clinic. While work continues developing new and improving existing immunotherapies, there remains a great deal of basic tumor immunology still to learn, information that can only lead to greater success in the clinic....
Clinical and translational oncology
9h
Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain
Abstract Purpose The Spanish Society of Medical Oncology (SEOM) has carried out a study to analyse the conditions of access to oncology drugs in clinical practice in Spain. For the first time, the access of predictive biomarkers has also been analyzed. Methods A questionnaire was sent to 146 hospitals in Spain to collect information on...
Clinical and translational oncology
9h
The importance of adjuvant treatment and primary anatomical site in head and neck basaloid squamous cell carcinoma survival: an analysis of the National Cancer Database
Abstract Purpose Basaloid squamous cell carcinoma (BSCC) of the head and neck is an aggressive and highly malignant variant of squamous cell carcinoma that accounts for 2% of head and neck cancers. Previous studies have not analyzed the significance of adjuvant chemoradiation and anatomical site within BSCC subtype and its impact on survival. Methods ...
Clinical and translational oncology
9h
Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer
Abstract Purpose Metastasis-directed therapy (MDT) is an investigational treatment option in patients with oligorecurrent prostate cancer (PCa). The aim of this retrospective study is to report oncologic outcome and toxicity of elective nodal radiotherapy (ENRT) in PCa patients affected by pelvic nodal oligorecurrence. Methods 41 consecutive...
Clinical and translational oncology
9h
 
Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters
Abstract Purpose We analysed our initial experience with SBRT in liver metastasis from colorectal cancer at our institution. Materials and methods Between January/2014 and December/2017, 22 patients with 31 LMCCR were treated. Local control (LC) was assessed using the Kaplan–Meier and log-rank tests. We analysed potential prognostic factors...
Clinical and translational oncology
9h
The new function of circRNA: translation
Abstract Circular RNAs (circRNAs) have been considered a special class of non-coding RNAs without 5′ caps and 3′ tails which are covalently closed RNA molecules generated by back splicing of mRNA. For a long time, circRNAs have been considered to be directly involved in various biological processes as functional RNA. In recent years, a variety of circRNAs have been found to have translational functions, and the resultant peptides also play biological roles in the emergence and...
Clinical and translational oncology
9h
Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma
Abstract Purpose Chordoma is a rare tumor of the skeletal system that is characterized by a high recurrence rate and treatment resistance. Given the common finding of immune dysregulation in chordoma, immunotherapy has emerged as potential treatment option. As an important immune checkpoint regulator, we evaluated cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression and its prognostic significance for patients with chordoma of...
Clinical and translational oncology
9h
A population perspective on the use of external beam radiotherapy in Catalonia, Spain
Abstract Purpose To assess the use of external beam radiotherapy in Catalonia (Spain), overall and by health management area. Methods We assessed radiotherapy treatments in a cohort of patients diagnosed with cancer from 2009 to 2011, using the population-based cancer registries in Girona and Tarragona. Participants had to have a minimum...
Clinical and translational oncology
9h
Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
Abstract Introduction The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S). Methods This study analyzed the prevalence, characteristics and...
Clinical and translational oncology
9h
The free amino acid profiles and metabolic biomarkers of predicting the chemotherapeutic response in advanced sarcoma patients
Abstract Purpose Metabolomics is an emerging field in cancer research. Plasma free amino acid profiles (PFAAs) have shown different features in various cancers, but the characteristic in advanced sarcoma remains unclear. We aimed to uncover the specific PFAAs in advanced sarcoma and to find the relationship between the altering of PFAAs and response to chemotherapy. ...
Clinical and translational oncology
9h
Endobronchial Carcinoids: Surgical Outcome in 100 Consecutive Patients and Factors Affecting Lung Preservation
Abstract Bronchial carcinoids are slow-growing tumours of the neuroendocrine family. Most of them have a benign course with excellent outcome after complete resection. Due to their location in the primary bronchi, adequate resection with lung preservation requires considerable technical expertise. In this paper we present our surgical experience with endobronchial carcinoids and analyse the factors that predict possibility of lung preservation surgery. Retrospective analysis of...
Latest Results for Indian Journal of Surgical Oncology
11h
2-Oxoglutarate-dependent dioxygenases in cancer
Nature Reviews Cancer, Published online: 21 October 2020; doi:10.1038/s41568-020-00303-3This Review discusses the metabolic regulation of 2-oxoglutarate-dependent dioxygenases (2OGDDs) and how dysregulation of 2OGDDs in cancer, by genetic aberrations or environmental factors including hypoxia and/or the action of oncometabolites, can contribute to tumour development and growth.
Nature Reviews Cancer - Issue - nature.com science feeds
11h
2-Oxoglutarate-dependent dioxygenases in cancer
Nature Reviews Cancer - Issue - nature.com science feeds
15h
Dosimetric evaluation of a rotating gamma-ray system for stereotactic body radiation therapy
Abstract Purpose Gamma-ray stereotactic radiosurgery systems available commercially contain either stationary or rotational source configuration. Rotational systems reduce the number of sources utilized and can also provide beneficial dosimetric properties. In this study, we explore the dosimetric advantage of a novel rotating gamma-ray design for stereotactic body radiotherapy (SBRT) as compared to the well-established CyberKnife system....
Latest Results for Journal of Radiation Oncology
11h
Intraoperative radiotherapy for early breast cancer — insufficient evidence to change practice
Nature Reviews Clinical Oncology, Published online: 21 October 2020; doi:10.1038/s41571-020-00444-2We argue that the evidence remains insufficient for use of intraoperative radiotherapy (IORT) in women with early stage breast cancer outside of a clinical trial, as the recently reported TARGIT-A trial does not provide sufficient evidence to conclude that IORT is superior to no radiotherapy.
Nat R Clinical Oncology
14h
Intraoperative radiotherapy for early breast cancer — insufficient evidence to change practice
Nat R Clinical Oncology
17h
Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium
Abstract Background Loss of the genomic stability jeopardize genome stability and promote malignancies. A fraction of ovarian cancer (OvCa) arises from pathological mutations of DNA repair genes that result in highly mutagenic genomes. However, it remains elusive why the ovarian epithelial cells are particularly susceptible to the malfunction of genome surveillance system. ...
Latest Results for BMC Cancer
15h
Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma
Abstract Background Osteosarcoma is a rare malignant bone tumor in adolescents and children. Poor prognosis has always been a difficult problem for patients with osteosarcoma. Recent studies have shown that tumor infiltrating immune cells (TIICs) are associated with the clinical outcome of osteosarcoma patients. The aim of our research was to construct a risk score model based on TIICs to predict the prognosis of patients with...
Latest Results for BMC Cancer
15h
Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies
Abstract Background Both intermittent intravenous (IIV) infusion and continuous intravenous (CIV) infusion of Endostar are widely used for NSCLC in China. We aimed to compare the efficacy and safety of CIV of Endostar versus IIV in combination with first-line chemotherapy for patients with advanced NSCLC. Methods RCTs, NRCTs and cohort...
Latest Results for BMC Cancer
15h
microRNA-451a promoter methylation regulated by DNMT3B expedites bladder cancer development via the EPHA2/PI3K/AKT axis
Abstract Background The downregulation of microRNA (miR)-451a has been reported in bladder cancer (BCa) tissues. Herein, we elucidated the role of miR-451a in BCa with the involvement of DNA methyltransferase 3B (DNMT3B). Methods We first screened the differentially expressed miRNAs from the serum of 12 BCa patients and 10 healthy controls...
Latest Results for BMC Cancer
15h
The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
Abstract Background The association between immune-related adverse events (irAEs) and survival outcomes in patients with advanced melanoma receiving therapy with immune checkpoint inhibitors (ICIs) has not been well established, particularly in Asian melanoma. Methods We retrospectively reviewed 49 melanoma patients undergoing therapy...
Latest Results for BMC Cancer
16h
Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling
Abstract Background Thirty to forty percent of patients with Diffuse Large B-cell Lymphoma (DLBCL) have an adverse clinical evolution. The increased understanding of DLBCL biology has shed light on the clinical evolution of this pathology, leading to the discovery of prognostic factors based on gene expression data, genomic rearrangements and mutational subgroups. Nevertheless, additional efforts are needed in order to enable...
Latest Results for BMC Cancer
16h
KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
CONCLUSION: This study suggests that KRAS expression can be used as a prognostic indicator of breast cancer, and it is closely related to tumor immune infiltration. PMID: 33067762 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Breast Cancer
15h
Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
CONCLUSIONS: Higher PFN2 expression is associated with a worse 10-year overall survival and relapse-free survival in breast cancer patients, as well as worse 10-year relapse-free survival in TNBC patients. PFN2 promotes the proliferation, migration and invasion of TNBC cells by regulating epithelial-to-mesenchymal transition. PMID: 33047272 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Breast Cancer
15h
Ann Oncol; +31 new citations
31 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2020/10/21PubMed comprises more than millions of citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites. (Source: Ann Oncol)
Ann Oncol
16h
Ann Oncol; +35 new citations
35 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Ann Oncol These pubmed results were generated on 2020/10/19PubMed comprises more than millions of citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites. (Source: Ann Oncol)
Ann Oncol
16h
Trends in cancer survival in the Nordic countries 1990-2016: the NORDCAN survival studies.
CONCLUSION: The reasons for the observed improvements in cancer survival are likely multifactorial, including earlier diagnosis, improved treatment options, implementation of national cancer plans, uniform national cancer care guidelines and standardized patient pathways. The previous survival disadvantage in Denmark is no longer present for most sites. Continuous monitoring of cancer survival is of importance to assess the impact of changes in policies and the effectiveness of health care systems....
Acta Oncologica
16h
Changes in health-related outcomes among colorectal cancer patients undergoing inpatient rehabilitation therapy: a systematic review of observational and interventional studies.
CONCLUSION: The scientific evidence level was very limited. Due to the lack of a comparison group in most studies, we were only able to evaluate changes during/after inpatient rehabilitation therapy but not the effectiveness of treatment. However, study findings suggest that physical health and functional independence improve during inpatient rehabilitation, but improvements wane over time. Further large representative studies, in particular RCTs with long-term follow-up, are essential to evaluate...
Acta Oncologica
16h
Data may save lives - cancer epidemiology needed to guide public health and clinical progress.
Authors: Storm HH PMID: 33073662 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
16h
Treatment-related leukopenia in anal cancer patients associated with worse outcome: results of a retrospective cohort study.
Authors: Nilsson MP, Scherman J, Gunnlaugsson A, Leon O, Johnsson A, Nilsson ED PMID: 33074041 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
16h
Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study.
CONCLUSION: Breast imaging modalities correctly estimated pathological tumor size in less than half of the tumors. Based on this finding, predicting residual tumor size post-NACT is challenging using conventional imaging. Patients with early radiological non-response might need improved monitoring during NACT and be considered for changed treatment plans. PMID: 33063567 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
16h
Incorporation of the LETd-weighted biological dose in the evaluation of breast intensity-modulated proton therapy plans.
CONCLUSION: Enhanced biological dose was observed compared to standard dose with assumed RBE of 1.1 for the heart, ribs, esophagus, and brachial plexus in breast/CW and regional nodal IMPT plans. Variable RBE models should be considered in the evaluation of the IMPT breast plans, especially for OARs located near the end of range of a proton beam. Clinical outcome studies are needed to validate model predictions for clinical toxicities. PMID: 33063569 [PubMed - as supplied by publisher] (Source:...
Acta Oncologica
16h
Estimates of lung and pancreatic cancer survival in Sweden with and without inclusion of death certificate initiated (DCI) cases.
CONCLUSIONS: Lung and pancreatic cancers are underreported to the SCR yielding too low incidence rates and upward biased survival estimates. We conclude that implementation of systematic death certificate processing with trace-back is feasible also within the Swedish system with regionalized cancer reporting. Verifying registrability by use of information in the Patient Register provided a good approximation of "corrected" survival estimates based on chart review. PMID: 33063588 [PubMed - as...
Acta Oncologica
16h
Incidence of head and neck cancer in adolescents and young adults: a Danish nationwide study from 1978-2014.
Authors: Jakobsen KK, Hjuler T, Laier GH, von Buchwald C, Grønhøj C PMID: 33054471 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Acta Oncologica
16h
Metabolic plasticity of IDH1 -mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
Abstract Background Targeting glutamine metabolism in cancer has become an increasingly vibrant area of research. Mutant IDH1 (IDH1mut) gliomas are considered good candidates for targeting this pathway because of the contribution of glutamine to their newly acquired function: synthesis of 2-hydroxyglutarate (2HG). Methods We have employed...
Latest Results for Cancer
16h
Laparoscopic versus open transhiatal approach for adenocarcinoma of the esophagogastric junction: A systematic review and meta-analysis
Publication date: Available online 20 October 2020Source: European Journal of Surgical OncologyAuthor(s): Xiao-Dong Chen, Fu-Qian He, Mao-Shan Liao, Mi Chen
ScienceDirect Publication: European Journal of Surgical Oncology (EJSO)
17h
Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
CONCLUSIONS: TMT with CF and CP produced comparable outcomes. However, for dCRT, CF may be a superior regimen. PMID: 33053548 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
17h
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
CONCLUSIONS: Despite the fact that second-line irinotecan plus gemcitabine combination therapy did not produce marked tumor shrinkage, it achieved a relatively high disease control rate of >65% with an acceptable toxicity profile. Hence, the combination of irinotecan plus gemcitabine may be considered for MPM treatment, with consideration of combination with immune checkpoint inhibitors as a potential next step. PMID: 33053560 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
17h
Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass.
Authors: Groisberg R, Subbiah V PMID: 33049750 [PubMed - as supplied by publisher] (Source: Oncology)
Oncology
17h
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery.
CONCLUSIONS: Natural language processing with machine learning improved the ability to predict postoperative complication and hospital readmission among women with ovarian cancer undergoing surgery. PMID: 33069375 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
17h
Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
CONCLUSIONS: In this retrospective cohort study, we demonstrate that in women with advanced EOC, HIPEC with MIS at the time of IDS following NACT is feasible. Our institutional experience demonstrates similar rates of R0 cytoreduction, compared to LAP. An MIS approach should not prevent surgeons from utilizing HIPEC where indicated for management of advanced EOC. PMID: 33067001 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
17h
Radiotherapy is not indicated in patients with vulvar squamous cell carcinoma and only one occult intracapsular groin node metastasis.
CONCLUSION: Because of the low risk of groin recurrence and the excellent groin recurrence-free survival, we recommend that adjuvant radiotherapy to the groin in patients with vulvar squamous cell carcinoma and a single occult intracapsular lymph node metastasis can be safely omitted to prevent unnecessary toxicity and morbidity. PMID: 33067000 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
17h
Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers.
CONCLUSIONS: SBRT offers a high rate of local control with low incidence of toxicity, mainly grade 1 GI toxicity and fatigue, and provides effective salvage therapy for oligometastatic extracranial pelvic and extra-pelvic gynecological tumors. PMID: 33059914 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
17h
Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
CONCLUSIONS: Young EOC patients are most often diagnosed at an early FIGO stage with LG serous or mucinous histology. Tumors are significantly more resistant to platinum-based chemotherapy in younger patients. PMID: 33059915 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
17h
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Authors: Haunschild CE, Tewari KS Abstract Advances in next generation sequencing have allowed for rapid and economical germline and tumor genomic profiling. Targeted therapies based on molecular tumor profiling are now integrated into treatment guidelines for many solid tumors. In epithelial ovarian cancer, 50% of tumors possess damaging mutations in homologous recombination repair genes (aka homologous recombination deficiency or HRD) which includes the BRCA genes. Deleterious BRCA mutations...
Gynecologic Oncology
17h
Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
CONCLUSION: MMR deficiency is associated with adverse prognostic factors and worse PFS among endometrioid tumors, particularly in early stage EC. MMR testing outside of LS screening has prognostic value, warranting consideration for inclusion as a biomarker in prospective clinical trials. PMID: 33046272 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Gynecologic Oncology
17h
Expression pattern analysis and drug differential sensitivity of cancer-associated fibroblasts in triple-negative breast cancer.
Authors: Li Q, Li M, Zheng K, Tang S, Ma S Abstract Triple-negative breast cancer (TNBC) has the characteristics of a complex molecular landscape, aggressive or high proliferation leading to poor prognosis, and behavioral heterogeneity. The purpose of the present study was to determine the spatiotemporal expression of α-smooth muscle actin (α-SMA)-positive cancer-associated fibroblasts (CAFs) at histological level in 4T1 tumors and to predict the sensitivity to 138 drugs in patients with...
Translational Oncology
17h
BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy.
Authors: Chen YY, Lo CF, Chiu TY, Hsu CY, Yeh TK, Chen CP, Huang CL, Huang CY, Wang MH, Huang YC, Ho HH, Chao YS, Shih JC, Tsou LK, Chen CT Abstract Zinc(II)-dipicolylamine (Zn-DPA) has been shown to specifically identify and bind to phosphatidylserine (PS), which exists in bulk in the tumor microenvironment. BPRDP056, a Zn-DPA-SN38 conjugate was designed to provide PS-targeted drug delivery of a cytotoxic SN38 to the tumor microenvironment, thereby allowing a lower dosage of SN38 that...
Translational Oncology
17h
Emerging roles for HMGA2 in colorectal cancer.
Authors: Wang X, Wang J, Wu J Abstract HMGA2 (High Mobility Group AT-hook 2) has been reported to promote colorectal cancer (CRC) development by regulating the transcription of target genes. It participates in nearly all aspects of cellular processes, including cell transformation, proliferation, apoptosis, senescence, metastasis, epithelial-to-mesenchymal transition (EMT), DNA repair and stem cell self-renewal. In the past decades, a group of downstream targets and binding partners have...
Translational Oncology
17h
Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer.
CONCLUSION: Additional knowledge of Enolase-1/ MBP-1 as a biomarker and its interactions within the Wnt signaling pathway and epithelial-mesenchymal transition potentially improve the prognosis of therapeutic approaches in EOC. PMID: 33069100 [PubMed - as supplied by publisher] (Source: Translational Oncology)
Translational Oncology
17h
Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response.
Authors: McCann E, O'Sullivan J, Marcone S Abstract Radiotherapy is a regimen that uses ionising radiation (IR) to treat cancer. Despite the availability of several therapeutic options, cancer remains difficult to treat and only a minor percentage of patients receiving radiotherapy show a complete response to the treatment due to development of resistance to IR (radioresistance). Therefore, radioresistance is a major clinical problem and is defined as an adaptive response of the tumour...
Translational Oncology
17h
Combination therapy: Future directions of immunotherapy in small cell lung cancer.
Authors: Huang W, Chen JJ, Xing R, Zeng YC Abstract Small cell lung cancer (SCLC), an aggressive and devastating malignancy, is characterized by rapid growth and early metastasis. Although most patients respond to first-line chemotherapy, the majority of patients rapidly relapse and have a relatively poor prognosis. Fortunately, immunotherapy, mainly including antibodies that target the cytotoxic T lymphocyte antigen-4 (CTLA-4), checkpoints programmed death-1 (PD-1), and programmed death-ligand...
Translational Oncology
17h
5-Aminolevulinic acid for fluorescence-guided surgery in pancreatic cancer: Cellular transport and fluorescence quantification studies.
Authors: Labib PL, Yaghini E, Davidson BR, MacRobert AJ, Pereira SP Abstract 5-Aminolevulinic acid (ALA) is a potential contrast agent for fluorescence-guided surgery in pancreatic ductal adenocarcinoma (PDAC). However, factors influencing ALA uptake in PDAC have not been adequately assessed. We investigated ALA-induced porphyrin fluorescence in PDAC cell lines CFPAC-1 and PANC-1 and pancreatic ductal cell line H6c7 following incubation with 0.25-1.0 mM ALA for 4-48 h. Fluorescence was...
Translational Oncology
17h
Non-invasive detection of biliary tract cancer by low-coverage whole genome sequencing from plasma cell-free DNA: A prospective cohort study.
DISCUSSION: Our results suggest that BTC harbors rich plasma CNV signals, and their assays might be useful for diagnosing BTC. PMID: 33059123 [PubMed - as supplied by publisher] (Source: Translational Oncology)
Translational Oncology
17h
Plasma thiobarbituric acid reactive substances predicts survival in chemotherapy na ïve patients with metastatic urothelial carcinoma.
In this study, high TBARS in MUC patients were associated with poor survival, likely due to more aggressive disease activity as reflected in increased liver involvement. Therefore, this biomarker could be used in clinical practice for early identification of patients with worse prognosis, better patient stratification, and treatment decision making. PMID: 33059122 [PubMed - as supplied by publisher] (Source: Translational Oncology)
Translational Oncology
17h
Transitional dynamics of cancer stem cells in invasion and metastasis.
Authors: Richard V, Kumar TRS, Pillai RM Abstract At the onset, few cancer cells amidst the tumor bulk, identified as cancer stem cells (CSCs) or early disseminated cancer cells (eDCCs) are capable of survival post conventional therapy and persist as minimal residual disease (MRD). Metastatic subclones emerge both early and late in the life of primary tumor ensuing an ongoing regional clonal evolution of progenitor cells in metastatic and primary tumors. In the last decade, multiple studies...
Translational Oncology
17h
Circulating microRNAs as biomarkers to assist the management of the malignant germ-cell-tumour subtype choriocarcinoma.
Authors: Murray MJ, Smith S, Ward D, Verduci L, Nicholson JC, Scarpini CG, Coleman N Abstract Germ-cell-tumours (GCTs) are heterogeneous and management is complex. The current conventional biomarkers, alpha-fetoprotein and human-chorionic-gonadotropin (HCG), have limited utility for diagnosis/follow-up as secretion is restricted to specific malignant-GCT subtypes and long half-life can make interpretation and clinical decision-making challenging. We sought to identify circulating microRNAs...
Translational Oncology
17h
Effectiveness of Ketogenic Diets on the Survival of Adult Oncological Patients.
Authors: Minzer S Abstract Cancer is the second most prevalent disease worldwide and it presents characteristic hallmarks common to all its types. Within these, it has been described a reprogramming of its energy metabolism, characterized by the preferential use of glucose as energy source in an aerobic glycolysis process. Although this feature may provide adaptive advantages to tumoral cells, it has been described as a weakness that could make them more vulnerable. The ketogenic diet,...
Nutrition and Cancer
17h
Herbal and Natural Dietary Products: Upcoming Therapeutic Approach for Prevention and Treatment of Hepatocellular Carcinoma.
Authors: Mandlik DS, Mandlik SK Abstract The most common tumor linked with elevated death rates is considered the hepatocellular carcinoma (HCC), sometimes called the malignant hepatoma. The initiation and progression of HCC are triggered by multiple factors like long term alcohol consumption, metabolic disorders, fatty liver disease, hepatitis B and C infection, age, and oxidative stress. Sorafenib is the merely US Food and Drug Administration (FDA)-approved drug used to treat HCC. Several...
Nutrition and Cancer
17h
Industrial Elimination of Essential Oils from Rosmarinus Officinalis: In Support of the Synergic Antifibrotic Effect of Rosmarinic and Carnosic Acids in Bleomycin Model of Lung Fibrosis.
In conclusion, industrial elimination of essential oils from rosemary allowed us to obtain two extracts with potent antifibrotic activities due to the large amount of RA and CA that appear much higher and effective than wild rosemary extract. PMID: 33059466 [PubMed - as supplied by publisher] (Source: Nutrition and Cancer)
Nutrition and Cancer
17h
Effect of Methionine on AMD1 Gene Expression in Prostate Cancer Cells.
CONCLUSION: MET has a significant regulatory effect on the expression of the AMD1 gene and a certain amount of MET can promote the expression of the AMD1 gene. This provides a health guideline for a low-methionine diet for prostate cancer patients and scientific evidence for prostate cancer prevention. PMID: 33054431 [PubMed - as supplied by publisher] (Source: Nutrition and Cancer)
Nutrition and Cancer
17h
Long non-coding RNA FALEC promotes colorectal cancer progression via regulating miR-2116-3p-targeted PIWIL1.
CONCLUSION: Our study revealed that FALEC promoted CRC progression via restoring the expression of miR-2116-3p-targeted PIWIL1, suggesting the potential application of targeting FALEC in the treatment of CRC. PMID: 33073675 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
Cancer Biology and Therapy
18h
FGF13 interaction with SHCBP1 activates AKT-GSK3 α/β signaling and promotes the proliferation of A549 cells.
In this study, the cell proliferation effect of FGF13 on A549 cells was checked by CCK-8, clone formation, Ki67 immunofluorescence staining and Flow Cytometry assay. Localization of FGF13 within A549 cells was performed with confocal laser scanning microscope. The protein variations and interaction were measured by western blotting and co-immunoprecipitation analysis. It showed that FGF13 was mainly distributed in the cytoplasm and exhibited a high expression level in A549 cells. High expression...
Cancer Biology and Therapy
18h
Metallophosphoesterase 1, a novel candidate gene in hepatocellular carcinoma malignancy and recurrence.
CONCLUSIONS: MPPE1 is a novel gene associated with HCC malignancy and recurrence. PMID: 33054568 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
Cancer Biology and Therapy
18h
Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer.
Cancer Biology and Therapy
18h
[New European approvals: Glasdegib for Acute myeloid leukemia].
Authors: Barrière S, Gastaud L PMID: 33070952 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
18h
[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology].
Authors: Billaud A, Chevalier LM, Campone M, Morel A, Bigot F Abstract Genomic instability is one of the main properties of tumour development, promoting first the acquisition of genetic alterations and thus carcinogenesis. Then, the chronic and anarchic proliferation of cancer cells also supports and contributes to this instability allowing a continuous evolution of the tumour. The accumulation of mutations resulting from that instability contributes to tumour heterogeneity that occurs...
Bulletin du Cancer
18h
[Perceptions and attitudes of nurses on emotional and sexual lives of cancer patients].
CONCLUSION: Nurses must acknowledge the existence of sexual health issues in cancer patients by rectifying their perceptions of sexuality, improving their knowledge and management of care, by addressing the issue of sexual health early enough. PMID: 33069338 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
18h
[Crohn's disease and autologous hemapoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Authors: Puyade M, Treton X, Alric L, Badoglio M, Castilla Llorente C, Fotsing G, Marjanovic Z, Rovira M, Terriou L, Torregrosa Díaz Jose M, Tran-Minh ML, Allez M, Pugnet G, Laharie D, Yakoub-Agha I, Farge D Abstract Crohn's Disease (CD) is an auto-inflammatory disease, which may involve the entire gastro-intestinal tract. CD is diagnosed on several clinical, biological, endoscopic and histological criteria. First line therapy is based on oral or iv steroids. In case of steroids dependence...
Bulletin du Cancer
18h
[Palliative care medical consultation in a hematology department. Feedback and critical reflection on a year of practice].
We describe the benefits that can be anticipated when collaboration increases between hematology and palliative care, including early on in the course of disease. It is now up to policy-makers to establish priorities regarding the allocation of health resources, in particular regarding end-of-life. This requires identifying patient needs, optimizing patient access to specialized palliative care, and improving the pertinence of palliative care interventions as they cannot be generalized. PMID:...
Bulletin du Cancer
18h
[Tumors affecting the temporomandibular joint  - a literature review].
[Tumors affecting the temporomandibular joint - a literature review]. Bull Cancer. 2020 Oct 12;: Authors: Schlund M, Roland-Billecart T, Aubert S, Nicot R Abstract Benign and malign tumors can affect the temporomandibular joint (TMJ) as any other articulation. Nevertheless, TMJ tumors are rare and mostly benign. Their clinical expression is varied including symptomatology similar to TMJ dysfunctional disorders, otologic or neurologic pathologies. In some cases, they remain...
Bulletin du Cancer
18h
[Influence of age on indications and modalities of radiation therapy: What to keep in mind for adolescents and young adults?]
This article highlights the key points of AYA care with radiation therapy. PMID: 33051053 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
18h
[New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy].
Authors: Boilève A, Samalin E PMID: 33046237 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Bulletin du Cancer
18h
Silver lining: reduced relapse with chronic GVHD after transplant for MDS.
Authors: Eckel AM, Deeg HJ Abstract Chronic graft-versus-host disease (GVHD) following hematopoietic cell transplantation is associated with reduced relapse incidence in patients with leukemias. This impact has been investigated in myelodysplastic syndrome, showing a beneficial impact of limited chronic GVHD on transplant outcomes in a cohort of more than 3,000 patients. PMID: 33067257 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
CONCLUSIONS: Pretreatment ctDNA is a reliable indicator of patient outcome in the first-line ICI treatment setting, but not in the second-line ICI setting, especially in patients pretreated with BRAF/MEK inhibitors. Preliminary evidence indicated that treatment-naïve patients with high ctDNA may preferentially benefit from combined ICIs. PMID: 33067256 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Hypo-fractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice.
CONCLUSION: The present results show that FLASH-RT delivered with hypo-fractionated regimens is able to spare the normal brain from radiation-induced toxicities without compromising tumor cure. This exciting capability provides an initial framework for future clinical applications of FLASH-RT. PMID: 33060122 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Editor's Note: Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma.
Authors: Tong T, Zhong Y, Kong J, Dong L, Song Y, Fu M, Liu Z, Wang M, Guo L, Lu S, Wu M, Zhan Q PMID: 33060290 [PubMed] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Selected Articles from This Issue.
Authors: PMID: 33060288 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
Authors: Chua V, Mattei J, Han A, Johnston L, LiPira K, Selig SM, Carvajal RD, Aplin AE, Patel SP Abstract Uveal melanoma (UM) is a rare cancer in adults but its treatment is one of the clinical unmet needs in the melanoma field. Metastatic disease develops in approximately 50% of patients and is associated with poor survival due to the lack of effective treatment options. It provides a paradigm for cancers that show evidence of aberrant G-protein coupled receptor signaling, tumor dormancy,...
Clinical Cancer Research
18h
Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter.
Authors: Birnbaum DJ, Finetti P, Birnbaum D, Bertucci F PMID: 33060289 [PubMed - in process] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
This article summarizes the FDA thought process and data supporting the favorable benefit-risk profile and approval of tucatinib. PMID: 33055172 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
TERT promoter mutation analysis for blood-based diagnosis and monitoring of gliomas.
CONCLUSIONS: Our results demonstrate the feasibility of detecting circulating cfDNA TERT promoter mutations in glioma patients with clinically relevant sensitivity and specificity. PMID: 33051308 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Similarities in Risk for COVID-19 and Cancer Disparities.
Authors: Newman L, Winn RA, Carethers JM Abstract Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread world-wide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed two-fold higher rate for hospitalization and greater than two-fold higher rate for death as compared to White Americans. The disparity seen with COVID-19 is consistent with patterns of disparities observed for...
Clinical Cancer Research
18h
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
CONCLUSIONS: Our data highlight the immunogenicity of stereotyped VH CDR3 sequences and support the feasibility and efficacy of their use for novel cancer vaccine in CLL. Such approach has the advantage to generate "off-the-shelf" therapeutic vaccines for relevant groups of patients belonging to stereotyped subsets. PMID: 33051305 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics.
Conclusions Nearly one in six patients with PDAC have tumors that fail to reliably fall into the classical or basal-like PDAC subtype categories, based on two regression tools aimed towards clinical practice. Rather, these patient tumors show intermediate prognostic and molecular traits. We propose close consideration of the non-binary nature of PDAC subtypes for future incorporation of subtyping into clinical practice. PMID: 33051307 [PubMed - as supplied by publisher] (Source: Clinical Cancer...
Clinical Cancer Research
18h
B7-H3: an attractive target for antibody-based immunotherapy.
Authors: Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S Abstract The recent impressive clinical responses to antibody-based immunotherapy have prompted the identification of clinically relevant tumor antigens that can serve as targets in solid tumors. Among them, B7-H3, a member of the B7 ligand family, represents an attractive target for antibody-based immunotherapy: it is overexpressed on differentiated malignant cells and cancer initiating cells, with...
Clinical Cancer Research
18h
Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling.
CONCLUSIONS: Our findings suggest TNO155 is an effective agent for blocking both tumor-promoting and immune-suppressive RTK signaling in RTK- and MAPK-driven cancers and their tumor microenvironment. Our data provide the rationale for evaluating these combinations clinically. PMID: 33046519 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Phase I Study of Lysine-Specific Demethylase-1 Inhibitor CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
CONCLUSIONS: CC-90011 is well-tolerated, with the RP2D established as 60 mg QW. The MTD and NTD were determined to be 80 mg QW and 120 mg QW, respectively. Further evaluation of CC-90011 is warranted. PMID: 33046517 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Serial circulating tumor DNA in predicting and monitoring the effect of neoadjuvant chemoradiotherapy in patients with rectal cancer: a prospective multicenter study.
CONCLUSIONS: We show that ctDNA is a real-time monitoring indicator that can accurately reflect the tumor burden. The median VAF of baseline ctDNA is a strong independent predictor of MFS. PMID: 33046514 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-Refractory Advanced Solid Tumors.
CONCLUSIONS: Single intratumoral injection of C. novyi-NT is feasible. Toxicities can be significant but manageable. Signals of anti-tumor activity and the host immune response support additional studies of C. novyi-NT in humans. PMID: 33046513 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Preclinical activity of SAR408701, a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors.
CONCLUSIONS: Based on these preclinical data, the ADC SAR408701 is a promising candidate for development as a potential treatment for patients with CEACAM5-positive tumors. PMID: 33046521 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Activity and Safety of Geptanolimab (GB226) for patients with unresectable, recurrent or metastatic alveolar soft part sarcoma: a phase 2 single-arm study.
CONCLUSIONS: Geptanolimab has clinically meaningful activity and a manageable safety profile in unresectable, recurrent or metastatic ASPS. PMID: 33046518 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer.
CONCLUSIONS: Ramucirumab plus osimertinib demonstrated encouraging safety and antitumor activity in T790M-positive EGFR-mutant NSCLC. PMID: 33046516 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma.
CONCLUSION: We identified a cyclin D1-dependent transcriptional program that is overexpressed in MCL and predicts clinical outcome. PMID: 33046520 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Three distinct stroma types in human pancreatic cancer identified by image analysis of fibroblast subpopulations and collagen.
CONCLUSIONS: This study identified three distinct stroma types differentially associated with survival, immunity and molecular features, thereby underscoring the importance of stromal heterogeneity in subtyping pancreatic cancers and supporting the development of anti-stromal therapies. PMID: 33046515 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Clinical Cancer Research
18h
Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma
Summary Molecular targeted therapies in pancreatic ductal adenocarcinoma (PDAC) lag behind treatment options in other tumor entities. The POLO trial has provided promising preliminary data for targeting gBRCA in PDAC by the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib. This review tries to show further potential approaches to exploit faulty DNA repair mechanisms beyond gBRCA and olaparib.
Magazine Eur Med Oncol
19h
Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis
Abstract Introduction There is no standard treatment for locoregional recurrent (LR) esophageal squamous cell carcinoma (ESCC) patients treated with radiotherapy (RT) previously. This retrospective study aimed to examine the efficacy and toxicity of re-irradiation (re-RT) for ESCC patients with LR. Patients and methods A total of 252...
Latest Results for Radiation Oncology
20h
Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer
AbstractAfrican American women are at increased risk of being diagnosed at a young age and/or with triple negative breast cancer, both factors which are included in current guidelines for identifying women who may benefit from genetic testing. Commercial breast cancer predisposition genetic panels, based largely on data derived from women of European ancestry, may not capture the full spectrum of cancer predisposition genes associated with breast cancer in African American women. Between 2001 and...
Familial Cancer
20h
A novel germline variant in RET gene resulting in an additional cysteine in a family with familial medullary thyroid carcinoma
We describe a novel c.1765A >  T variant ofRET proto-oncogene in a family with medullary thyroid carcinoma (MTC) that predicts the creation of an additional cysteine p.(Ser589Cys) in the cysteine-rich domain. In this site only three other punctual variants have been described, giving rise to extra cysteines. We have characterized the clinical phenotype of this family. The index case was a 79-year-old woman with MTC in both thyroid lobes. This variant co-segregates in this family in four affected...
Familial Cancer
20h
The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer
AbstractBreast cancer is the most frequent event in Li-Fraumeni syndrome associated with germlineTP53 variants. Some studies have shown that breast cancers in women with Li-Fraumeni syndrome are commonly HER2-positive, suggesting thatHER2 amplification or over-expression in a young woman may be a useful criterion to test for germline variants in theTP53 gene. We assessed the prevalence of germlineTP53 variants by Sanger sequencing or next-generation sequencing in 149 women with HER2-positive breast...
Familial Cancer
20h
CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF- κB signaling
CD137 is a target for tumor immunotherapy. However, the role of CD137 in gastric cancer (GC), especially in inducing GC cell apoptosis, has not been studied. (Source: Cancer Cell International)
Cancer Cell International
21h
Is Needle Localization Painful?
Title: Is Needle Localization Painful?Category: Diseases and ConditionsCreated: 10/20/2020 12:00:00 AMLast Editorial Review: 10/20/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
21h
Is Lumpectomy a Major Surgery?
Title: Is Lumpectomy a Major Surgery?Category: Diseases and ConditionsCreated: 10/20/2020 12:00:00 AMLast Editorial Review: 10/20/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
21h
Is a Mastectomy Major Surgery?
Title: Is a Mastectomy Major Surgery?Category: Diseases and ConditionsCreated: 10/20/2020 12:00:00 AMLast Editorial Review: 10/20/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
21h
What You Need to Know About Your Colon Cancer Risk
Title: What You Need to Know About Your Colon Cancer RiskCategory: Health NewsCreated: 10/19/2020 12:00:00 AMLast Editorial Review: 10/20/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
21h
How Many Lymph Nodes Are in Axillary Dissection?
Title: How Many Lymph Nodes Are in Axillary Dissection?Category: Diseases and ConditionsCreated: 10/19/2020 12:00:00 AMLast Editorial Review: 10/19/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
21h
Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin α5-fibronectin pathway
Peritoneal metastasis (PM) is an important pathological process in the progression of gastric cancer (GC). The metastatic potential of tumor and stromal cells is governed by hypoxia, which is a key molecular f... (Source: Journal of Experimental and Clinical Cancer Research)
Journal of Experimental and Clinical Cancer Research
21h
Correction to: The role of microRNA-133b and its target gene FSCN1 in gastric cancer
An amendment to this paper has been published and can be accessed via the original article. (Source: Journal of Experimental and Clinical Cancer Research)
Journal of Experimental and Clinical Cancer Research
21h
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor with limited therapeutic options. Recent data suggest that histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K) pathway play ... (Source: Journal of Experimental and Clinical Cancer Research)
Journal of Experimental and Clinical Cancer Research
21h
CCR Grand Rounds - Targeting Hormone-Driven DNA Repair in Prostate Cancer: Mechanisms and Clinical Implications
Date: Friday, 11 06, 2020; Speaker: Karen E Knudsen, Executive Vice President, Sidney Kimmel Cancer Center; https://bit.ly/2H1VLTP; CME Credit; Videocast Event (Source: NIH Calendar of Events)
MedWorm Cancer & Oncology Events
21h
CCR Grand Rounds - Metabolic Barriers to Effective Cancer Immunotherapy
Date: Friday, 11 20, 2020; Speaker: Greg M Delgoffe, University of Pittsburgh; https://bit.ly/3k1SO49; CME Credit; Videocast Event (Source: NIH Calendar of Events)
MedWorm Cancer & Oncology Events
21h
Next Generation Sequencing and Tumor Initiation and Progression
Date: Tuesday, 11 03, 2020; Speaker: Christina Curtis, Ph.D., M.Sc., Assistant Professor of Medicine and Genetics, Stanford Cancer Institute; https://epi.grants.cancer.gov/events/seqSPACE/ (Source: NIH Calendar of Events)
MedWorm Cancer & Oncology Events
21h
Neuroblastoma: A Developmental Neuroscience Approach to Childhood Cancer
Date: Monday, 10 26, 2020; Speaker: Nina Schor, MD, PhD, Deputy Director, NINDS/NIH; Zoom, invitation under Other information; Videocast Event (Source: NIH Calendar of Events)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
MedWorm Cancer & Oncology Events
21h
Early Cancer Research Careers: Building Professional Resilience and Supportive Networks in Uncertain Times
Date: Monday, 11 09, 2020; Speaker: Kimberly Bertrand, Sc.D., M.P.H., Assistant Professor of Medicine,, Boston University; Julianne Lunde, M.A., Program Manager, Lymphoma Epidemiology Laboratory, Mayo Clinic; Lauren McCullough, Ph.D., M.S.P.H., Assistant Professor of Epidemiology, , Emory University; Rosalie Waller, Ph.D., Research Associate, Biomedical Statistics and Informatics, Mayo Clinic; https://epi.grants.cancer.gov/cohort-consortium/ (Source: NIH Calendar of Events)
MedWorm Cancer & Oncology Events
21h
COVID19 Pandemic: Natural Experiment in Rural Cancer Care Telehealth Capacity
Oct 30, 2020. . Sponsored by National Cancer Institute (Source: Rural events via the Rural Assistance Center)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
MedWorm Cancer & Oncology Events
21h

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου